Identity Oriented Psychotrauma Therapy on Hashimoto in Adults
Identity Oriented Psychotrauma Therapy on Hashimoto in Adults
The purpose of this study is to evaluate whether Identity Oriented Psychotrauma Therapy
 (IOPT) is effective in decreasing the level of autoantibodies of patients with Hashimoto
 thyroiditis. The investigators hypothesize that working Constellations of Intention will have
 a positive impact on the biological level, by decreasing the level of autoantibodies,
 antithyroglobulin antibody (anti-Tg) and anti-thyroid peroxidase antibody (anti-TPO), which
 are the main antibodies detected in chronic autoimmune thyroiditis. Secondly, it will have an
 impact on the psyche by decreasing the level of dissociation, alexithymia, anger, and by
 increasing the quality of life and than those in the control group.
Hashimoto thyroiditis is an autoimmune disease that leads to chronic inflammation of the
 thyroid gland. This is considered the most common autoimmune disorder, and the most common
 endocrine disorder. Psychological trauma has been suggested as a possible factor in the
 pathogenesis and development of autoimmune diseases. Although a diversity of
 psychotherapeutic interventions have been studied in adults with autoimmune diseases, there
 is a lack of psychological research and randomized controlled trials in the field of the
 Hashimoto disease. This study is designed to be a clinical trial with two arms: one
 experimental and one control group. The experimental group receives IOPT and the control
 group is a waiting list. 70 out-patients with Hashimoto disease will be randomly assigned to
 the two groups. The investigators hypothesize that the therapeutic gains will be more
 significant in the experimental condition than in the control groups at the completion of the
 therapy and that this will be maintained at the 3-month follow-up.The IOPT group undergoes 10
 group modules of IOPT once at two weeks.The sessions will be conducted by clinicians or
 psychotherapists specialized in IOPT. If therapy is efficient on the autoimmune disorder,
 participants in the control group will be reallocated to IOPT after the experimental
 treatment will come to an end.
Inclusion Criteria:

 -  aged 18-60 years;

 -  confirmed autoimmune thyroiditis diagnosis

 -  at least one biological marker Anti-thyroid peroxidase (anti-TPO) antibodies or
 thyroglobulin antibodies (TgAb) exceeds the reference range

 Exclusion Criteria:

 -  the presence of psychotic symptoms

 -  currently receiving another form of psychological treatment;

 -  under psychotropic medication;

 -  neurodevelopmental disorders (intellectual disability, communication disorders, autism
 spectrum disorders, ADHD);

 -  neurocognitive disorders;

 -  substance abuse;

 -  serious legal or health issues that would prevent from regularly attending

 -  patients with autoimmune thyroiditis with biological markers within the reference
 range